Home45E • FRA
add
Natera Inc
Previous close
€173.00
Day range
€173.00 - €173.00
Year range
€164.00 - €216.00
Market cap
28.05B USD
Avg Volume
10.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 665.50M | 39.79% |
Operating expense | 468.21M | 28.50% |
Net income | 47.26M | 187.89% |
Net profit margin | 7.10 | 162.89% |
Earnings per share | 0.36 | 187.80% |
EBITDA | -13.69M | 77.35% |
Effective tax rate | 454.63% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.08B | 11.14% |
Total assets | 2.40B | 44.41% |
Total liabilities | 685.93M | 47.41% |
Total equity | 1.71B | — |
Shares outstanding | 141.73M | — |
Price to book | 14.11 | — |
Return on assets | -2.70% | — |
Return on capital | -3.37% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | 47.26M | 187.89% |
Cash from operations | 73.89M | 39.71% |
Cash from investing | -71.59M | -543.93% |
Cash from financing | 32.41M | 195.30% |
Net change in cash | 34.70M | -34.21% |
Free cash flow | 16.99M | -69.31% |
About
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments in San Carlos, California and Austin, Texas. Wikipedia
Founded
Jan 1, 2004
Headquarters
Website
Employees
6,138
